PDCD5

Programmed cell death protein 5 · O14737 · PDCD5 on Sugi Atlas →

8 patent compounds predicted against PDCD5, 6 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL21943762 SCHEMBL21943762 0.57 1/20
SCHEMBL21944043 SCHEMBL21944043 0.55 1/20
SCHEMBL21943004 SCHEMBL21943004 0.55 1/20
SCHEMBL21942995 SCHEMBL21942995 0.53 1/20
SCHEMBL21943411 SCHEMBL21943411 0.53 1/20
SCHEMBL21943540 SCHEMBL21943540 0.49 1/20

Clinical trials — most relevant to PDCD5 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
co Ihibtory Receptor in Preeclampsia PHASE4UNKNOWN
Effect of Tramadol Versus Morphine on PD1 and PD1-ligand in Patients With Chronic Cancer Pain PHASE2/PHASE3UNKNOWN
Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564) PHASE3COMPLETED
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) PHASE3COMPLETED
PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma PHASE3COMPLETED
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension PHASE3COMPLETED
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma PHASE2RECRUITING
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study) PHASE1/PHASE2WITHDRAWN
Pembrolizumab (MK-3475) in MM Patients With Residual Disease PHASE2COMPLETED
Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer PHASE2RECRUITING
Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation PHASE2UNKNOWN
Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary PHASE2UNKNOWN
Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668) PHASE2WITHDRAWN
Trimodal Therapy Plus Atezolizumab in Muscle-invasive Bladder Cancer PHASE2UNKNOWN
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007) PHASE2COMPLETED
Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease PHASE2COMPLETED
Neoadjuvant Pembrolizumab for Muscle-invasive Urothelial Bladder Carcinoma PHASE2COMPLETED
Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer PHASE2COMPLETED
A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer PHASE2UNKNOWN
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors. PHASE2NOT_YET_RECRUITING
Personalized Vaccine With SOC Chemo Followed by Nivo in Pancreatic Cancer PHASE1ACTIVE_NOT_RECRUITING
Study on the Safety and Tolerability of PD-1 Knockout Tumor-infiltrating T Cells (TILs) in the Treatment of Advanced Colorectal Cancer PHASE1RECRUITING
Effect of Severe Trauma on PD1 and Its Legend (PD1/L1) on T Lymphocytes and Correlation With Mortality nanUNKNOWN
Role of Programmed Death Ligand 1 in Colorectal Cancer nanNOT_YET_RECRUITING
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
Effect of Anesthesia on Expression of Programmed Death-1 and Programmed Death-1 Ligand in Breast Cancer nanUNKNOWN
Modulatory Effect of Prodigiosin or Pioglitazone on TIME and the Crosstalk to Immune-Checkpoint Protein(s) nanNOT_YET_RECRUITING
Immuno-Oncology Database and Bioregistry nanACTIVE_NOT_RECRUITING
National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer nanACTIVE_NOT_RECRUITING
Soluble Programmed Death 1 (sPD1) is a Diagnostic Biomarker of ILD in Patients With Rheumatoid Arthritis Disease nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a PDCD5 binder may also engage these)

ProteinNameSimilarity
Q5RBT0 1.000 Q5RBT0 →
P56812 0.988 P56812 →
Q2HJH9 0.972 Q2HJH9 →
Q9D8B3 0.950 Q9D8B3 →
CHMP4B Charged multivesicular body protein 4b 0.947 landscape →
Q5ZHP5 0.946 Q5ZHP5 →
Q9SZE4 0.945 Q9SZE4 →
P50502 0.945 P50502 →
O82197 0.943 O82197 →
Q5XGW6 0.943 Q5XGW6 →
Q7ZVC4 0.942 Q7ZVC4 →
B5FZ63 0.941 B5FZ63 →
Q5RF31 0.940 Q5RF31 →
Q6GL11 0.938 Q6GL11 →
ENY2 Transcription and mRNA export factor ENY2 0.938 landscape →
Q3ZBJ0 0.938 Q3ZBJ0 →
Q5RBR3 0.937 Q5RBR3 →
Q9NZZ3 0.937 Q9NZZ3 →
Q5ZLF0 0.937 Q5ZLF0 →
Q99L47 0.937 Q99L47 →
Q9JIX0 0.936 Q9JIX0 →
P50503 0.935 P50503 →
Q4QQV8 0.934 Q4QQV8 →
Q6IQ73 0.934 Q6IQ73 →
Q9D7S9 0.934 Q9D7S9 →
Q6PBL0 0.933 Q6PBL0 →
Q8NFI4 0.932 Q8NFI4 →
P49205 0.931 P49205 →
Q6ZVM7 0.930 Q6ZVM7 →
P48788 0.930 P48788 →